Clinical trials
Phase 1/2 Carcinoma, Transitional Cell trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
61 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 8 |
| 2018 | 6 |
| 2019 | 8 |
| 2020 | 4 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Terminated | 16 |
| Recruiting | 14 |
| Active, not recruiting | 13 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Incyte Biosciences International Sàrl | 3 |
| Merck Sharp & Dohme LLC | 3 |
| National Cancer Institute (NCI) | 3 |
| Astellas Pharma Global Development, Inc. | 2 |
| Eli Lilly and Company | 2 |
| Rainier Therapeutics | 2 |
| AEterna Zentaris | 1 |
| Alentis Therapeutics AG | 1 |
| Altor BioScience | 1 |
| Aprea Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Transitional Cell | 61 |
| Carcinoma, Non-Small-Cell Lung | 26 |
| Urinary Bladder Neoplasms | 20 |
| Melanoma | 16 |
| Squamous Cell Carcinoma of Head and Neck | 15 |
| Carcinoma, Renal Cell | 14 |
| Uterine Cervical Neoplasms | 14 |
| Colorectal Neoplasms | 13 |
| Ovarian Neoplasms | 12 |
| Stomach Neoplasms | 12 |
Trials
Showing 1 to 25 of 61. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.